Transdiscal administration of high affinity anti-MMP inhibitors

Details Transdiscal administration of high affinity anti-MMP inhibitors Transdiscal administration of high affinity anti-MMP inhibitors

2003-06-30

2008-09-30

Marschel, Ardin H. (Department: 1614)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

Reexamination Certificate

active

07429378

ABSTRACT:
The present invention relates to injecting a high affinity antagonist of MMPs into a diseased intervertebral disc.

REFERENCES:
patent: 3678158 (1972-07-01), Sussman
patent: 4341867 (1982-07-01), Johansen
patent: 4427649 (1984-01-01), Dingle et al.
patent: 4435506 (1984-03-01), Jackson et al.
patent: 4696816 (1987-09-01), Brown
patent: 5095037 (1992-03-01), Iwamitsu et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5223248 (1993-06-01), McNamara et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5258371 (1993-11-01), Golub et al.
patent: 5270300 (1993-12-01), Hunziker
patent: 5368841 (1994-11-01), Trauner et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5510370 (1996-04-01), Hock
patent: 5656272 (1997-08-01), Le et al.
patent: 5656644 (1997-08-01), Adams et al.
patent: 5728396 (1998-03-01), Peery et al.
patent: 5833984 (1998-11-01), Eibl et al.
patent: 5942499 (1999-08-01), Radomsky
patent: 5965583 (1999-10-01), Beers et al.
patent: 6049026 (2000-04-01), Muschler
patent: 6277969 (2001-08-01), Le et al.
patent: 6284471 (2001-09-01), Le et al.
patent: 6340369 (2002-01-01), Ferree
patent: 6352557 (2002-03-01), Ferree
patent: 6419944 (2002-07-01), Tobinick
patent: 6541477 (2003-04-01), Lewicki et al.
patent: 6554830 (2003-04-01), Chappius
patent: 6590081 (2003-07-01), Zhang
patent: 6623472 (2003-09-01), Reincke et al.
patent: 6713246 (2004-03-01), Reinecke et al.
patent: 6756215 (2004-06-01), Wolfraim et al.
patent: 2001/0006948 (2001-07-01), Kang et al.
patent: 2001/0016195 (2001-08-01), Tobinick
patent: 2001/0026801 (2001-10-01), Tobinick
patent: 2002/0010471 (2002-01-01), Wironen et al.
patent: 2002/0026244 (2002-02-01), Trieu
patent: 2002/0032155 (2002-03-01), Ferree
patent: 2002/0082697 (2002-06-01), Damien
patent: 2002/0107200 (2002-08-01), Chang et al.
patent: 2002/0169162 (2002-11-01), Smith et al.
patent: 2002/0198599 (2002-12-01), Haldimann
patent: 2003/0007972 (2003-01-01), Tobinick
patent: 2003/0039651 (2003-02-01), Olmarker
patent: 2003/0049256 (2003-03-01), Tobinick
patent: 2003/0069639 (2003-04-01), Sander et al.
patent: 2003/0134792 (2003-07-01), Pike et al.
patent: 2003/0207827 (2003-11-01), Boyle et al.
patent: 2004/0022864 (2004-02-01), Freyman et al.
patent: 2004/0126372 (2004-07-01), Banerjee et al.
patent: 2004/0193274 (2004-09-01), Trieu
patent: 2004/0229786 (2004-11-01), Attawia et al.
patent: 2004/0229878 (2004-11-01), DiMauro et al.
patent: 2005/0025765 (2005-02-01), DiMauro et al.
patent: 2005/0038001 (2005-02-01), Attawia et al.
patent: 2005/0100538 (2005-05-01), Attawia et al.
patent: 2005/0112091 (2005-05-01), DiMauro et al.
patent: 2007/0237777 (2007-10-01), DiMauro et al.
patent: 0 218 868 (1987-04-01), None
patent: 0 288 088 (1988-10-01), None
patent: 0 438 234 (1991-07-01), None
patent: 0 950 417 (1999-10-01), None
patent: 1 133 995 (2001-09-01), None
patent: 1 153 607 (2001-11-01), None
patent: 1 464 307 (2004-10-01), None
patent: WO 91/02078 (1991-02-01), None
patent: WO 92/07076 (1992-04-01), None
patent: WO 92/16553 (1992-10-01), None
patent: WO 93/16099 (1993-08-01), None
patent: WO 97/28828 (1997-08-01), None
patent: WO 98/24477 (1998-06-01), None
patent: WO 99/45923 (1999-09-01), None
patent: WO 01/85179 (2001-11-01), None
patent: WO 02/057240 (2002-07-01), None
patent: WO 02/100387 (2002-12-01), None
patent: WO 02/100387 (2002-12-01), None
patent: WO 03/ 000190 (2003-01-01), None
patent: WO2004/022078 (2004-03-01), None
patent: WO 2005/000283 (2005-01-01), None
patent: WO 2005/110276 (2005-11-01), None
patent: WO 2006/031376 (2006-03-01), None
Haro et al J. Clinical Investigation (2000) 100(2) pp. 143-150.
Goupille et al. (Spine) V. 23(14) 1612-1626 (1998).
Ohno et al. Anaesth. Analg 1997; 85:1312-1316.
Ahn, N.U., et al., “Effect of Nutrient Concentration and OP-1 on the Metabolism of Intervertebral Disc: In Vitro Organ Culture Study,” 28, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
Allali, F. et al., “Increase in Bone Mineral Density of Patients with Spondyloarthropathy Treated with Anti-Tumour Necrosis Factor α ,”Ann. Rheum. Dis., 62:347-349 (2003).
Andonopoulos, A.P., et al., “Intra-articular Anti-Tumor Necrosis Factor α Antibody in Recalcitrant Arthritis of Behcet's Disease,”Clinical and Experimental Rheumatology 21(4 Suppl 30): S-57-S58 (Jul.-Aug. 2003).
Arai, I., et al., “Pretreatment with Loxoprofen Sodium, 6-OHDA or Anti TNF-Alpha Antibody Reduce Fos-Like Immunoreactivity in Rat Experimental Lumber Disc Herniation,” 111, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
Ariga, K., et al., “Mechanical Stress-Induced Apoptosis of Endplate Chondrocytes in Organ-Cultured Mouse Intervertebral Discs,”Spine, 28(14):1528-1533 (2003).
Ashkenazi, A., et al., “Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin,”Proc. Natl. Acad. Sci. USA, 88:10535-10539 (1991).
Baker, D., et al. “Control of Established Experimental Allergic Encephalomyelitis by Inhibition of Tumor Necrosis Factor (TNF) Activity Within the Central Nervous System Using Monoclonal Antibodies and TNF Receptor-Immunoglobulin Fusion Proteins,”Eur. J. Immunol., 24:2040-2048 (1994).
Biskobing, D.M., “Novel Therapies for Osteoporosis,”Expert Opinion Invest. Drugs, 12(4):611-621 (2003).
Boehm, J.C., et al., “New Inhibitors of p38 Kinase,”Exp. Opin, Ther. Patents, 10(1):25-37 (2000).
Bokarewa, M., et al., “Local Infusion of Infliximab for the Treatment of Acute Joint Inflammation,”Ann. Rheum Dis., 62: 783-784 (2003).
Braun, J. And Sieper, J., “Overview of The Use of The Anti-TNF Agent Infliximab in Chronic Inflammatory Diseases,”Expert Opin. Biol. Ther., 3(1):141-168 (2003).
Braun, J., et al., “Anti-Tumor Necrosis Factor α Therapy for Ankylosing Spondylitis: International Experience,”Ann. Rheum. Dis., 61(Supp. III):iii51-iii60 (2002).
Bringman, T.S., et al., “Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Application for Affinity Purification, Immunoassays, and as Structural Probes,”Hybridoma, 6(5):489-507 (1987).
Burke, J. G., et al., “Human Nucleus Pulposus Secretes Transforming Growth Factor Beta-1 and Basic Fibroblast Growth Factor,” 189, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
Butler, D.M., et al., “TNF Receptor Fusion Proteins are Effective Inhibitors of TNF-Mediated Cytotoxicity on Human KYM-1D4 Rhabdomyosarcoma Cells,”Cytokine, 6(6):616-623 (1994).
Capon, D.J., et al. “Designing CD4 Immunoadhesins for AIDS Therapy,”Nature, 337:525-531 (1989).
Cardone, D.A., et al., “Diagnostic and Therapeutic Injection of the Hip and Knee,”Family Medicine, 67(10):2147-2152 (2003).
Cirillo, P.F., et al., “The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors,”Current Topics in Medicinal Chemistry, 2:1021-1035 (2002).
Connolly, J., et al., “Development of an Osteogenic Bone-Marrow Preparation,”The Journal of Bone and Joint Surgery, Inc., 71-A (5): 684-691 (1989).
Conti, F., et al., “Successful Treatment with Intraarticular Infliximab for Resistant Knee Monarthritis in a Patient with Spondylarthropathy,”Arthritis&Rheumatism, 52(4): 1224-1226 (2005).
Corcoran, A.E., et al., “Characterization of Ligand Binding by the Human p55 Tumour-Necrosis-Factor Receptor,”Eur. J. Biochem., 223:831-840 (1994).
Cornefjord, M., et al., “Cerebrospinal Fluid Biomarkers in Experimental Spinal Nerve Root Injury,” 38, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
Crandall, C., &#

Affiliated with

Also associated with

Rating

Transdiscal administration of high affinity anti-MMP inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transdiscal administration of high affinity anti-MMP inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdiscal administration of high affinity anti-MMP inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3985838